Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

Medical News

Gilead Gains European Approval to Market Combination Antiretroviral Drug Truvada

February 25, 2005

Foster City, Calif.-based biotech company Gilead on Wednesday received approval from the European Commission to market its combination antiretroviral drug Truvada in all 25 European Union countries, the AP/Forbes reports. Truvada is a once-daily combination pill containing the antiretroviral drugs Emtriva and Viread, known generically as emtricitabine and tenofovir, respectively. The drugs work by blocking HIV's reverse transcriptase enzyme to prevent viral replication (AP/Forbes, 2/23). The drug was approved for marketing in the United States in August 2004, according to San Francisco Business Times (San Francisco Business Times, 2/23).

Back to other news for February 25, 2005


Reprinted with permission from kaisernetwork.org. You can view the entire Kaiser Daily HIV/AIDS Report, search the archives, or sign up for email delivery at www.kaisernetwork.org/dailyreports/hiv. The Kaiser Daily HIV/AIDS Report is published for kaisernetwork.org, a free service of the Kaiser Family Foundation, by The Advisory Board Company. © 2004 by The Advisory Board Company and Kaiser Family Foundation. All rights reserved.



  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily HIV/AIDS Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.
 
See Also
More HIV News
Advertisement:
Find out how a Walgreens specially trained pharmacist can help you

Tools
 

Advertisement